Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Kirkstone Metals Grants Stock Options (The Newswire) +++ KIRKSTONE METALS Aktie -3,65%

PFIZER Aktie

 >PFIZER Aktienkurs 
22.15 EUR    -0.7%    (Tradegate)
Ask: 22.16 EUR / 721 Stück
Bid: 22.09 EUR / 724 Stück
Tagesumsatz: 113507 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
PFIZER Aktie über LYNX handeln
>PFIZER Performance
1 Woche: +1,1%
1 Monat: +1,9%
3 Monate: +6,8%
6 Monate: +4,9%
1 Jahr: -14,0%
laufendes Jahr: +4,1%
>PFIZER Aktie
Name:  PFIZER INC. DL-,05
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US7170811035 / 852009
Symbol/ Ticker:  PFE (Frankfurt) / PFE (NYSE)
Kürzel:  FRA:PFE, ETR:PFE, PFE:GR, NYSE:PFE
Index:  S&P500
Webseite:  https://www.pfizer.com/
Profil:  Pfizer Inc. is a multinational pharmaceutical and ..
>Volltext..
Marktkapitalisierung:  126916.61 Mio. EUR
Unternehmenswert:  167018.41 Mio. EUR
Umsatz:  54132.47 Mio. EUR
EBITDA:  22546.21 Mio. EUR
Nettogewinn:  8445.99 Mio. EUR
Gewinn je Aktie:  1.49 EUR
Schulden:  53207.34 Mio. EUR
Liquide Mittel:  1157.92 Mio. EUR
Operativer Cashflow:  11274.83 Mio. EUR
Bargeldquote:  0.41
Umsatzwachstum:  -0.9%
Gewinnwachstum:  117.53%
Dividende je Aktie:  1.48 EUR
Dividendenrendite:  6.64%
Dividendenschätzung:  6.64%
Div. Historie:  07.11.25 - 0.371649€
25.07.25 - 0.36894€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  PFIZER
Letzte Datenerhebung:  17.01.26
>PFIZER Kennzahlen
Aktien/ Unternehmen:
Aktien: 5685.71 Mio. St.
Frei handelbar: 99.91%
Rückkaufquote: -
Mitarbeiter: 81000
Umsatz/Mitarb.: 0.68 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 9.65%
Bewertung:
KGV: 15.15
KGV lG: 8.33
KUV: 2.35
KBV: 1.59
PEG-Ratio: 0.12
EV/EBITDA: 7.41
Rentabilität:
Bruttomarge: 69.12%
Gewinnmarge: 15.6%
Operative Marge: 30.99%
Managementeffizenz:
Gesamtkaprendite: 4.58%
Eigenkaprendite: 10.59%
 >PFIZER Anleihen 
Es sind 4 Anleihen zur PFIZER Aktie bekannt.
>PFIZER Peer Group

Es sind 591 Aktien bekannt.
 
16.01.26 - 10:06
Pfizer Aktie: Patentabläufe belasten - Kompensiert Obesity die Rückgänge wirklich? (Aktiencheck)
 
Wien (www.aktiencheck.de) - Pfizer-Aktienanalyse von der Raiffeisen Bank International AG: Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), nimmt die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) in einer aktuellen Aktienanalyse unter die Lupe. [mehr]...
15.01.26 - 06:48
3SBio Sees More Business Development Deals (Bloomberg)
 
Tony He, CFO of the Chinese biopharmaceutical firm 3SBio, discusses his outlook for dealmaking and the progress of a record licensing deal the company struck with Pfizer last year. He speaks on “Bloomberg: The China Show” from San Francisco, where the JPMorgan Healthcare Conference is taking place. (Source: Bloomberg)...
15.01.26 - 01:00
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note (Zacks)
 
In the latest trading session, Pfizer (PFE) closed at $25.56, marking a +1.63% move from the previous day....
14.01.26 - 18:42
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference (CNBC)
 
Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the JPMorgan Healthcare Conference....
14.01.26 - 15:15
PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock (Zacks)
 
Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious....
13.01.26 - 23:06
Novo′s CEO Is Ready to Go ′Very Big′ in Hunt for Obesity Deals (Bloomberg)
 
Novo Nordisk A/S is back on the hunt for deals to boost its obesity portfolio after losing US biotech Metsera Inc. in a bidding war with Pfizer Inc. late last year....
13.01.26 - 15:15
Inside Pfizer′s Oncology Performance Ahead of Q4 Results (Zacks)
 
PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures....
13.01.26 - 01:48
Stocks Rise as Credit Card Shares Slip on Trump Rate Cap Talk | The Close 1/12/2026 (Bloomberg)
 
Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are Former Federal Reserve Governor Betsy Duke, GE HealthCare's Peter Arduini, CFRA's Ken Leon, Zoetis' Kristin Peck, Morgan Stanley's Lauren Hochfelder, Blackrock's Jay Jacobs, Cornell University's Eswar Prasad, PGIM's Cathy Marcus, Elanco Animal Health's Jeff Simmons, Pfizer's Albert Bourla. (Source: Bloomberg)...
13.01.26 - 00:57
Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra (Reuters EN)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
12.01.26 - 23:03
Pfizer seeking priority voucher from Trump administration - report (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.01.26 - 21:54
Pfizer Talking to Trump Administration About Priority Vouchers (Bloomberg)
 
Pfizer Inc. is looking to join its rivals in getting priority review vouchers, Chief Executive Officer Albert Bourla said, after several drugmakers received the express passes after striking deals with the White House on pricing....
12.01.26 - 21:06
Pfizer Looking for ′Superior′ Results on Weight-Loss Drugs, CEO Says (Bloomberg)
 
Pfizer CEO Albert Bourla says the company is looking for "superior" results on weight-loss drugs. Speaking with Katie Greifeld at JPMorgan's annual health-care conference in San Francisco, Bourla also says he is "very satisfied" with Pfizer's current portfolio. (Source: Bloomberg)...
12.01.26 - 19:00
MDGL Secures Exclusive Global Right for MASH Treatment From PFE (Zacks)
 
Madrigal Pharmaceuticals obtains global rights to Pfizer's ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for MASH....
12.01.26 - 13:12
Vibrant Therapeutics Raises $61M and Appoints Han Lee, Ph.D. as Co-CEO (Business Wire)
 
New investors include Pfizer Ventures and Apricot Capital with proceeds to advance pipeline and global expansion Vibrant's lead solid tumor program, VIB305, is a logic-gated, dual-targeting masked T-cell engager for EGFR-positive solid tumors and recently received US FDA IND acceptanceGUANGZHOU, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vibrant Therapeutics (“Vibrant”), a clinical-stage biotechnology company developing next-generation intelligent therapeutics, today announced $61 million in new financing. The financing includes new investors Pfizer Ventures and Apricot Capital with participation from Bayland Capital, HSG, Northern Light Venture Capital, and First Principle Venture Limited. This brings Vibrant's total capital raised to $100 million. The company also announced the appointment of Han Lee, Ph.D., as co-chief executive officer (CEO), and the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its lead program, VIB305, for the treatment...
10.01.26 - 17:01
Pfizer′s BRAFTOVI Regimen Boosts Response Rates In BRAF V600E-Mutant Metastatic Colorectal Cancer (AFX)
 
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced positive results from Cohort 3 of the pivotal BREAKWATER trial, evaluating BRAFTOVI (encorafenib) in combination with cetuximab (ERBITUX) and ......
09.01.26 - 20:12
Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
09.01.26 - 16:00
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 (Fool)
 
It could be another tough year for the once-soaring drugmaker....
09.01.26 - 15:06
Pfizer inks licensing deal with Madrigal for MASH candidate (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.01.26 - 14:03
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor (GlobeNewswire EN)
 
CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, strengthening the company's leadership in shaping the next generation of MASH therapies and combination regimens. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inflammation in the liver....
09.01.26 - 03:45
Monsanto Sues COVID-19 Vaccine Manufacturers, Alleging Copyright Infringement (ZeroHedge)
 
Monsanto Sues COVID-19 Vaccine Manufacturers, Alleging Copyright Infringement Authored by Zachary Stieber via The Epoch Times, Bayer and its Monsanto division are suing COVID-19 vaccine manufacturers, alleging they used technology Monsanto developed and patented in the 1980s in their vaccines. Bayer said in lawsuits that Pfizer, its partner BioNTech, and Moderna wrongly used technology Monsanto developed and used to make plants resistant to insects. Pfizer-BioNTech and Moderna included the technology in their shots to enhance the stability of messenger ribonucleic acid (mRNA) “and thus the vaccines' ability to confer immunity to the virus,” lawyers for Bayer and Monsanto said in the suits, which were filed on Jan. 6 with the U.S. court in Delaware. Bayer was not involved in COVID-19 vaccine manufacturing or production. Bayer said it was not seeking to interfere with the production of the COVID-19 vaccines, which are still being made and sold, but said the court should award it money, desc...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ich habe zu Wien im Moment ein Verhältnis wie zu einer Mutter, die mich permanent verprügelt. - Rainhard Fendrich
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!